Table 2.
Summary of studies on the effects of tumour necrosis factor (TNF)-antagonists on anti-cyclic citrullinated peptide (CCP) levels.
| Author (reference) | Year | Disease duration | Treatment | Study length | Outcome |
|---|---|---|---|---|---|
| Alessandri 39 | 2004 | n.s.† | MTX + infliximab | 24 weeks | Reduced anti-CCP levels |
| Bobbio-Pallavicini 40 | 2004 | 9·4 years | MTX + infliximab | 78 weeks | No reduction in anti-CCP levels |
| Caramaschi 41 | 2005 | 12·6 years | MTX or AZA + infliximab | 22 weeks | No reduction in anti-CCP levels |
| De Rycke 42 | 2005 | n.s.‡ | MTX + infliximab | 30 weeks | No reduction in anti-CCP levels |
| Atzeni 43 | 2006 | 6–8 years | MTX versus MTX + adalimumab | 48 weeks | Reduced anti-CCP levels only in group treated with adalimumab |
| Chen 44 | 2006 | 8–9·5 years | MTX versus MTX + etanercept | 24 weeks | Reduced anti-CCP levels |
| Cuchacovich 45 | 2008 | – | MTX + adalimumab | 24 weeks | Reduced anti-CCP levels |
| Vis 46 | 2008 | 10 years | MTX + infliximab | 46 weeks | Reduced anti-CCP levels |
| Bacquet-Deschryver 47 | 2008 | 8 years | MTX or LEF + anti-TNF | 52–104 weeks | No reduction in anti-CCP levels |
| Bos 48 | 2008 | 7·9–9·5 years | MTX + adalimumab | 28 weeks | Reduced anti-CCP levels |
| Bruns 49 | 2009 | – | Oral DMARD + infliximab | 48 weeks | No reduction in anti-CCP levels |
†
Not stated (n.s.): ‘failed therapy with at least one prior disease-modifying anti-rheumatic drug (DMARD)’; n.s.: ‘refractory RA’. MTX: methotrexate; AZA: azathioprine; LEF: leflunomide.